Epstein-Barr virus (EBV) is a human herpesvirus that selectively binds to and infects human B lymphocytes (B cells). In the studies presented here, we found that several phenothiazines, including trifluoperazine, chlorpromazine, prochlorpromazine, and promethazine, blocked EBV infectivity of isolated adult human B cells as measured either by outgrowth of transformed cell colonies-or by [3ll~thymidine incorporation. Trifluoperazine, chlorpromazine, and prochlorpromazine were equally effective with 20 ,uM fully inhibiting infectivity, whereas 100 ,AM promethazine was required for a comparable effect. Inhibition by trifluoperazine was partially reversible. Studies with radiolabeled EBV demonstrated that the inhibitors did not impair virus binding to B cells. Electron microscopic examination of B lymphocytes revealed that trifluoperazine reduced the number of large uncoated cell vacuoles and the number of membrane microvilli, indicating that this agent interfered with cell pinocytosis. This process was accompanied by inhibition of EBV endoeytosis iQto B cells.
accompanied by inhibition of EBV endoeytosis iQto B cells.
Phenothiazines bind to and inhibit calmodulin, an intracellular calcium-binding protein that regulates several key enzymes, some of which directly affect cytoskeletal elements, although they alsQ may interact nonspecifically with other cellular constituents. In this regard, haloperidol, a non-phenothiazine calmodulin antagonist, and R24571, a derivative of the antimycotic miconazole, which is a potent and highly specific calmodulin inhibitor, also blocked EBV infection. These studies suggest that calmodulin or a calmodulin-regulated cellular enzyme(s) is involved in normal cellular endocytic processes in B lymphocytes and thereby in the early stages of EBV infection.
Recent studies in our laboratory have shown that EpsteinBarr virus (EBV) infects normal human B cells by an endocytic pathway that is somewhat different (1) than the clathrin-receptosome-lysosome pathway used by many other protein ligands (2) as well as several viruses (3) to enter cells. One difference in the endocytic pathway of EBV in normal B cells is the lack of participation of clathrin-coated pits and vesicles in the infectious process. The studies presented here were undertaken to further examine the early events in EBV infection and particularly the' mechanisms involved in EBV endocytosis into normal B lymphocytes. One element that provides an early signal for me'mbrane protein redistribution (capping) and cell activation processes in lymphocytes is intracellular calcium (4) (5) (6) (7) (8) .. Caltcium ions markedly influence many biological processes in lymphocytes, including capping but not patching, cytoplasjnic streaming, endocytosis, and exocytosis (4, 9-11). The effects of calcium on several important cell enzymes such as mefhbrane-associated Ca2+, Mg2+-ATPase, phosphodiesterase, and myosin light chain kinase implicated in the above noted cellular activities are regulated by the intracellular calcium-binding protein calmodulin (7, 9, (12) (13) (14) . In pursuing our studies of the mechanisms involved in the early stages of infection of human B lymphocytes by EBV, we have examined the ability of several classes of calmodulin antagonists to block EBV infection and determined the stage at which the infection process is altered. MATERIALS EBV was isolated from the B95-8 cell line as described (15 (17) and by outgrowth of transformed B-cell colonies, which were enumerated 7-14 days after infection by phase-contrast light microscopy (15 (Fig. 1 ).
Fifty percent inhibition was achieved with -5 ,AM trifluoperazine, whereas inhibition was nearly complete at 11 AtM.
Several other phenothiazines, including prochlorperazine, chlorpromazine, and promethazine, also blocked EBV infection (Table 1) , whereas the unsubstituted parent compound, phenothiazine, lacked inhibitory activity at the highest concentration of drug tested (Fig. 1) . In other experiments, 20 ,M phenothiazine failed to inhibit infectivity (data not shown). Haloperidol, a butyrophenone, also inhibited infectivity, although it was approximately 1/5th to 1/10th as effective as trifluoperazine in blocking infection. By contrast, R24571, a highly specific calmodulin inhibitor (18), was 5 times more potent than trifluoperazine (Fig. 1) ; complete inhibition of EBV infection was achieved with 3 ,uM R24571. Inhibition of viral infectivity by the above antagonists also occurred when these agents were added simultaneously with EBV. Further experiments were carried out to determine whether inhibition of EBV infectivity was reversible. In these studies, trifluoperazine was incubated with the cells for 30 min at 370C, after which the cells were washed prior to the addition of EBV. As shown in Fig. 2 , inhibition of viral transformation by trifluoperazine was partially reversible, with 50-60% of infectivity being restored after several wash steps. Trifluoperazine failed to inhibit infectivity if added after the cells and EBV had been in contact for 5 min at 370C, suggesting that the drug was acting at a stage early in the internalization process.
Effect of Phenothiazines and Other Calmodulin Antagonists on EBV Attachment. To determine whether the calmodulin inhibitors interfered with EBV attachment, B cells were treated with varying doses of the drugs and subsequently incubated with purified 35S-EBV. As shown in Fig. 3 
DISCUSSION
In these studies, several phenothiazines and non-phenothiazines inhibited the infection of B lymphocytes by EBV. These agents were found to inhibit infection by retarding internalization of EBV into large thin-walled endocytic vesi- cles (Figs. 4 and 5) ; attachment of EBV to cell surface viral receptors was unaffected ( Fig. 3 ; Table 2 ). Previous studies have shown that the EBV endocytic pathway in normal B lymphocytes proceeds exclusively via internalization into such vesicles and does not involve clathrin-coated pits and vesicles or fusion of endocytic vesicles with lysosomes (1), in sharp distinction to the clathrin-receptosome-lysosome pathway utilized by a number of protein ligands (2), including several viruses (3).
The drugs capable of retarding EBV infection, although of different chemical structures, are known to be potent inhibitors of the intracellular calcium-binding protein calmodulin (9, 11, 19) . Inhibition of calmodulin-mediated intracellular events follows the firm binding of such agents to calciumcalmodulin complexes (11, 19, 20) . Although the present studies have not directly shown calmodulin to be involved in endocytosis, and thus in EBV internalization, this is probable for the following reasons: (i) R24571, a highly specific calmodulin antagonist, which, unlike trifluoperazine, does not bind to a-adrenergic receptors (18) , also blocked EBV infectivity (Table 1 ; Fig. 1); (ii) the concentrations of the phenothiazines trifluoperazine and chlorpromazine required to inhibit EBV infection (Table 1) are similar to those reported to inhibit other calmodulin-dependent activities (11, (19) (20) (21) (22) ; (iii) promethazine, a phenothiazine, and haloperidol, a butyrophenone, were considerably less efficient than trifluoperazine in inhibiting both EBV infection (Table 1 ) and calmodulin-dependent activation of phosphodiesterase (21, 23) ; and (iv) the limited time frame for expression of drug-induced inhibition (Fig. 2 ) was similar to comparable findings for other calmodulin-dependent reaction. These aspects render it likely that the actions were mediated through calmodulin and not via one of the reported nonspecific actions of phenothiazines on cells (23, 24) .
The mechanisms involved in receptor-mediated endocytosis in nucleated cells are complex and involve several distinct reaction sequences (4) and at least two endocytic pathways (25, 26) . In addition to the clathrin-receptosome-lysosomal endocytic pathway that has been studied extensively in cultured cell lines (2, 3) , there exists another endocytic pathway in lymphocytes and other cells (12, (25) (26) (27) (28) (29) (30) that does not involve clathrin-coated vesicles but, rather, is characterized by membrane internalization and the random formation of large thin-walled vesicles (1, 12, 25 (4, 31) . Thus, the rise of intracellular calcium levels is followed by receptor-ligand clustering, which, in the case of membrane immunoglobulin, is accompanied by redistribution of cytoplasmic myosin beneath the membrane-receptor ligand complexes (32) (33) (34) . The recruitment of myosin and perhaps other cytoskeletal elements, including tubulin (22) and a-actinin (35) , to the site of receptor aggregates probably brings about the contractile force necessary for endocytosis. The redistribution of myosin during capping has been shown to be blocked by calmodulin antagonists (10) and calmodulin has been found to redistribute with caps of various types in lymphocytes (5, 7, 13, 14) . Endocytosis of immunoglobulin complexes, concae navalin A, and a2-macroglobulin are also inhibited by phenothiazines (12, 13, 36) . Taken together, these observations suggest that one pathway of endocytosis involves a series of events initiated by a rapid increase in intracellular calcium brought about by receptor cross-linking, which leads to activation of calmodulin at the cytoplasmic cell surface: activation of this protein allows activation of one of several potential cellular enzymes, such as myosin light chain kinase, whose activity is regulated by calmodulin (5, 37, 38) . The activation of this enzyme then generates functionally active myosin molecules capable of interacting with actin microfilaments. Thus, calmodulin activation might be the key step for physically linking cell membrane receptor-ligand complexes to the cytoskeletal system or alternatively by activating the contractile systems of the cell.
The present studies indicate that calmodulin or calmodulin-dependent processes are involved in the earliest stages of infection of normal human cells by a member of the herpesvirus family, EBV. Few therapeutic agents are available for the treatment of infection by herpesviruses. Calmodulin antagonists, including several phenothiazines and haloperidol, are widely used in clinical medicine as tranquilizers and antipsychotic agents and thus their actions and side effects are known. Since the classes of drugs studied here varied in their effectiveness in blocking EBV infection and simple substitutions markedly influenced activity in this regard (Table 1) , other types of agents or various chemical alterations may represent or yield even more potent anti-viral agents. Identification of the process or enzyme(s) regulated by calmodulin and involved in EBV endocytosis may also provide other approaches to blocking the early stages of infection. Such investigations may provide useful therapeutic agents for controlling herpesvirus infections in man.
